EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis

Chen-Yi Yuan, Yuan-Cheng Gao, Yi Lin, Lin Liu, Xiao-Gang Shen, Wen-Li Zou, Min-Min Wang, Quan-Quan Shen, Li-Na Shao, Yue-Ming Liu, Jia-Wei Zhang, Zhi-Hui Pan und 4 weitere

American Journal of Nephrology · 2024 · 55 (1) · 1-17

DOI: 10.1159/000534366 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift American Journal of Nephrology, online erschienen am 04.10.2023. Verfasst von Chen-Yi Yuan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Urology and Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical Colleg…. Hauptthemen laut MEDLINE: Hyperkalemia, Renal Insufficiency, Chronic, Kidney Failure, Chronic, Acute Kidney Injury. Die Arbeit wurde bisher 21-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mineralocorticoid receptor blockade could be a potential approach for the inhibition of chronic kidney disease (CKD) progression. The benefits and harms of different mineralocorticoid receptor antagonists (MRAs) in CKD are inconsistent.

Objectives

The aim of the study was to summarize the benefits and harms of MRAs for CKD patients.

Methods

We searched MEDLINE, EMBASE, and the Cochrane databases for trials assessing the effects of MRAs on non-dialysis-dependent CKD populations. Treatment and adverse effects were summarized using meta-analysis.

Results

Fifty-three trials with 6 different MRAs involving 22,792 participants were included. Compared with the control group, MRAs reduced urinary albumin-to-creatinine ratio (weighted mean difference [WMD], −90.90 mg/g, 95% CI, −140.17 to −41.64 mg/g), 24-h urinary protein excretion (WMD, −0.20 g, 95% CI, −0.28 to −0.12 g), estimated glomerular filtration rate (eGFR) (WMD, −1.99 mL/min/1.73 m2, 95% CI, −3.28 to −0.70 mL/min/1.73 m2), chronic renal failure events (RR, 0.86, 95% CI, 0.79–0.93), and cardiovascular events (RR, 0.84, 95% CI, 0.77–0.92). MRAs increased the incidence of hyperkalemia (RR, 2.04, 95% CI, 1.73–2.40) and hypotension (RR, 1.80, 95% CI, 1.41–2.31). MRAs reduced the incidence of peripheral edema (RR, 0.65, 95% CI, 0.56–0.75) but not the risk of acute kidney injury (RR, 0.94, 95% CI, 0.79–1.13). Nonsteroidal MRAs (RR, 0.66, 95% CI, 0.57–0.75) but not steroidal MRAs (RR, 0.20, 95% CI, 0.02–1.68) significantly reduced the risk of peripheral edema. Steroidal MRAs (RR, 5.68, 95% CI, 1.26–25.67) but not nonsteroidal MRAs (RR, 0.52, 95% CI, 0.22–1.22) increased the risk of breast disorders.

Conclusions

In the CKD patients, MRAs, particularly in combination with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, reduced albuminuria/proteinuria, eGFR, and the incidence of chronic renal failure, cardiovascular and peripheral edema events, whereas increasing the incidence of hyperkalemia and hypotension, without the augment of acute kidney injury events. Nonsteroidal MRAs were superior in the reduction of more albuminuria with fewer peripheral edema events and without the augment of breast disorder events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperkalemiaRenal Insufficiency, ChronicKidney Failure, ChronicAcute Kidney InjuryHypotensionHumansMineralocorticoid Receptor AntagonistsAlbuminuriaEdema

Stichwörter der Autor:innen

Chronic kidney diseaseDiabetic kidney diseaseMeta-analysisMineralocorticoid receptor antagonists

Substanzen

Mineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Urology and Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
  • Department of Nephrology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
  • Department of Nephrology, Zhejiang Hospital of Chinese Medicine, Affiliated to Zhejiang University of Chinese Medicine, Hangzhou, China.
  • Department of Nephrology, Hangzhou Hospital of Chinese Medicine (Guangxing Hospital), Affiliated to Zhejiang University of Chinese Medicine, Hangzhou, China.
  • Department of Nephrology, Yueqing People's Hospital, Wenzhou, China.

Zitieren

APA

Yuan, C. Y., Gao, Y. C., Lin, Y., Liu, L., Shen, X. G., Zou, W. L., Wang, M. M., Shen, Q. Q., Shao, L. N., Liu, Y. M., Zhang, J. W., Pan, Z. H., Zhu, Y., Yu, J. T., Yu, X. G., & Zhu, B. (2024). Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis. American Journal of Nephrology, 55(1), 1-17. https://doi.org/10.1159/000534366

Vancouver

Yuan CY, Gao YC, Lin Y, Liu L, Shen XG, Zou WL, et al. Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis. American Journal of Nephrology. 2024;55(1):1-17. doi:10.1159/000534366

BibTeX
@article{Yuan2024,
  author = {Yuan, Chen-Yi and Gao, Yuan-Cheng and Lin, Yi and Liu, Lin and Shen, Xiao-Gang and Zou, Wen-Li and Wang, Min-Min and Shen, Quan-Quan and Shao, Li-Na and Liu, Yue-Ming and Zhang, Jia-Wei and Pan, Zhi-Hui and Zhu, Yan and Yu, Jing-Ting and Yu, Xu-Guang and Zhu, Bin},
  title = {Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis},
  journal = {American Journal of Nephrology},
  year = {2024},
  volume = {55},
  number = {1},
  pages = {1--17},
  doi = {10.1159/000534366}
}
Kostenlos starten →